Ultragenyx Analyst Day Presentation

Capital allocation focused on key clinical and commercials programs Uses of Cash1 11 Declining YoY Cash Used in Operations expected to be less than $400M in 2024 Ongoing revenue growth and continued expense management create path to profitability in 2026 Cash and equivalents² of $777M as of December 31, 2023 2022a 2023a 2024e ■Cash Used in Operations ■GTMF CapEx/Non-recurring 1 Cash used in operations, Gene Therapy Manufacturing Facility (GTMF) Capital Expenses and select non-recurring uses of cash; estimated values for 2024 2 Cash, cash equivalents, and available-for-sale investments as of December 31, 2023 7 Confidential and Proprietary ultragenyx

View entire presentation